Leerink Partners Maintains Outperform on OmniAb, Raises Price Target to $12

10/7/2026
Impact: 70
Healthcare

Leerink Partners analyst Puneet Souda has maintained an 'Outperform' rating on OmniAb (NASDAQ: OABI) and raised the price target from $10 to $12. This adjustment reflects a positive outlook for the company's performance in the market.

AI summary, not financial advice

Share: